BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

595 related articles for article (PubMed ID: 19486012)

  • 1. Gene expression profiling of advanced-stage serous ovarian cancers distinguishes novel subclasses and implicates ZEB2 in tumor progression and prognosis.
    Yoshihara K; Tajima A; Komata D; Yamamoto T; Kodama S; Fujiwara H; Suzuki M; Onishi Y; Hatae M; Sueyoshi K; Fujiwara H; Kudo Y; Inoue I; Tanaka K
    Cancer Sci; 2009 Aug; 100(8):1421-8. PubMed ID: 19486012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BTF4/BTNA3.2 and GCS as candidate mRNA prognostic markers in epithelial ovarian cancer.
    Le Page C; Ouellet V; Quinn MC; Tonin PN; Provencher DM; Mes-Masson AM
    Cancer Epidemiol Biomarkers Prev; 2008 Apr; 17(4):913-20. PubMed ID: 18398031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells.
    Okamoto A; Nikaido T; Ochiai K; Takakura S; Saito M; Aoki Y; Ishii N; Yanaihara N; Yamada K; Takikawa O; Kawaguchi R; Isonishi S; Tanaka T; Urashima M
    Clin Cancer Res; 2005 Aug; 11(16):6030-9. PubMed ID: 16115948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome.
    Tothill RW; Tinker AV; George J; Brown R; Fox SB; Lade S; Johnson DS; Trivett MK; Etemadmoghadam D; Locandro B; Traficante N; Fereday S; Hung JA; Chiew YE; Haviv I; ; Gertig D; DeFazio A; Bowtell DD
    Clin Cancer Res; 2008 Aug; 14(16):5198-208. PubMed ID: 18698038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High insulin-like growth factor-2 (IGF-2) gene expression is an independent predictor of poor survival for patients with advanced stage serous epithelial ovarian cancer.
    Sayer RA; Lancaster JM; Pittman J; Gray J; Whitaker R; Marks JR; Berchuck A
    Gynecol Oncol; 2005 Feb; 96(2):355-61. PubMed ID: 15661221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers.
    Berchuck A; Iversen ES; Lancaster JM; Pittman J; Luo J; Lee P; Murphy S; Dressman HK; Febbo PG; West M; Nevins JR; Marks JR
    Clin Cancer Res; 2005 May; 11(10):3686-96. PubMed ID: 15897565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of gene expression in early-stage ovarian cancer.
    Marchini S; Mariani P; Chiorino G; Marrazzo E; Bonomi R; Fruscio R; Clivio L; Garbi A; Torri V; Cinquini M; Dell'Anna T; Apolone G; Broggini M; D'Incalci M
    Clin Cancer Res; 2008 Dec; 14(23):7850-60. PubMed ID: 19047114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relative expression levels of Th1 and Th2 cytokine mRNA are independent prognostic factors in patients with ovarian cancer.
    Kusuda T; Shigemasa K; Arihiro K; Fujii T; Nagai N; Ohama K
    Oncol Rep; 2005 Jun; 13(6):1153-8. PubMed ID: 15870936
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differentially androgen-modulated genes in ovarian epithelial cells from BRCA mutation carriers and control patients predict ovarian cancer survival and disease progression.
    Motamed-Khorasani A; Jurisica I; Letarte M; Shaw PA; Parkes RK; Zhang X; Evangelou A; Rosen B; Murphy KJ; Brown TJ
    Oncogene; 2007 Jan; 26(2):198-214. PubMed ID: 16832351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human kallikrein 8 (hK8/TADG-14) expression is associated with an early clinical stage and favorable prognosis in ovarian cancer.
    Shigemasa K; Tian X; Gu L; Tanimoto H; Underwood LJ; O'Brien TJ; Ohama K
    Oncol Rep; 2004 Jun; 11(6):1153-9. PubMed ID: 15138549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microarray expression identification of differentially expressed genes in serous epithelial ovarian cancer compared with bulk normal ovarian tissue and ovarian surface scrapings.
    Grisaru D; Hauspy J; Prasad M; Albert M; Murphy KJ; Covens A; Macgregor PF; Rosen B
    Oncol Rep; 2007 Dec; 18(6):1347-56. PubMed ID: 17982616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The clinical role of phospholipase A2 isoforms in advanced-stage ovarian carcinoma.
    Gorovetz M; Baekelandt M; Berner A; Trope' CG; Davidson B; Reich R
    Gynecol Oncol; 2006 Dec; 103(3):831-40. PubMed ID: 16919315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overexpression of ZEB2 at the invasion front of colorectal cancer is an independent prognostic marker and regulates tumor invasion in vitro.
    Kahlert C; Lahes S; Radhakrishnan P; Dutta S; Mogler C; Herpel E; Brand K; Steinert G; Schneider M; Mollenhauer M; Reissfelder C; Klupp F; Fritzmann J; Wunder C; Benner A; Kloor M; Huth C; Contin P; Ulrich A; Koch M; Weitz J
    Clin Cancer Res; 2011 Dec; 17(24):7654-63. PubMed ID: 22042972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis.
    Lu KH; Patterson AP; Wang L; Marquez RT; Atkinson EN; Baggerly KA; Ramoth LR; Rosen DG; Liu J; Hellstrom I; Smith D; Hartmann L; Fishman D; Berchuck A; Schmandt R; Whitaker R; Gershenson DM; Mills GB; Bast RC
    Clin Cancer Res; 2004 May; 10(10):3291-300. PubMed ID: 15161682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential.
    Meinhold-Heerlein I; Bauerschlag D; Hilpert F; Dimitrov P; Sapinoso LM; Orlowska-Volk M; Bauknecht T; Park TW; Jonat W; Jacobsen A; Sehouli J; Luttges J; Krajewski M; Krajewski S; Reed JC; Arnold N; Hampton GM
    Oncogene; 2005 Feb; 24(6):1053-65. PubMed ID: 15558012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene expression profiling of epithelial ovarian tumours correlated with malignant potential.
    Warrenfeltz S; Pavlik S; Datta S; Kraemer ET; Benigno B; McDonald JF
    Mol Cancer; 2004 Oct; 3():27. PubMed ID: 15471544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic analysis of early- versus late-stage ovarian tumors.
    Shridhar V; Lee J; Pandita A; Iturria S; Avula R; Staub J; Morrissey M; Calhoun E; Sen A; Kalli K; Keeney G; Roche P; Cliby W; Lu K; Schmandt R; Mills GB; Bast RC; James CD; Couch FJ; Hartmann LC; Lillie J; Smith DI
    Cancer Res; 2001 Aug; 61(15):5895-904. PubMed ID: 11479231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of trypsinogen-1, trypsinogen-2, and tumor-associated trypsin inhibitor in ovarian cancer: prognostic study on tissue and serum.
    Paju A; Vartiainen J; Haglund C; Itkonen O; von Boguslawski K; Leminen A; Wahlström T; Stenman UH
    Clin Cancer Res; 2004 Jul; 10(14):4761-8. PubMed ID: 15269150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: identification of novel molecular biomarkers for early diagnosis and therapy.
    Bignotti E; Tassi RA; Calza S; Ravaggi A; Romani C; Rossi E; Falchetti M; Odicino FE; Pecorelli S; Santin AD
    Gynecol Oncol; 2006 Nov; 103(2):405-16. PubMed ID: 16725184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Screening for genes associated with ovarian cancer prognosis.
    Chang XH; Zhang L; Yang R; Feng J; Cheng YX; Cheng HY; Ye X; Fu TY; Cui H
    Chin Med J (Engl); 2009 May; 122(10):1167-72. PubMed ID: 19493465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.